CompanyOCS OCSAWNasdaqZug, V8

Oculis

Oculis develops neuroprotective and immunomodulatory therapies for neuro-ophthalmology and ophthalmology.

SEC EDGAR ClinicalTrials.gov medicalmex.com

6-KSep 30Latest SEC filing

Sep 30Latest story

September 2026

Oculis board member Lionel Carnot resigns after nearly a decade

Sep 30PeopleOculis

July 2026

Oculis posts terminated Phase 3 OCS-01 cataract trial results after administrative error

Jul 30Trial updateOCS-01 Oculis